Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Expanding Spectrum of Desmin-Related Myopathy, Long-term Follow-up, and Cardiac Transplantation
Shelly, Shahar , Pereira, Naveen L. , Engel, Andrew G. , Johnson, Jonathan N. , Selcen, Duygu , Talha, Niaz, Shahar, Shelly , Niaz, Talha

Mayo Clinic

Neurology | July 27, 2021 | Volume: 97 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000012542 | PMID 34315782 Get It

Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
Frank, Ryan D. , Dage, Jeffrey L. , Jeromin, Andreas, Ashton, Nicholas J. , Blennow, Kaj , Karikari, Thomas K. , Vanmechelen, Eugeen , Lowe, Val J. , Bu, Guojun , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Jack, Clifford R. , Petersen, Ronald C. , Jack, Clifford R , Vemuri, Prashanthi , Bu, Guojun , Ashton, Nicholas J , Dage, Jeffrey L , Mielke, Michelle M. , Karikari, Thomas K. , Zetterberg, Henrik , Algeciras‐Schimnich, Alicia , Knopman, David S.

Mayo Clinic

JAMA Neurology | July 26, 2021 | Volume: 78 | Issue: 9 | Pages: 1108

10.1001/jamaneurol.2021.2293 | PMID 34309632 Get It

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline
Aakre, Jeremiah A. , Proctor, Nicholas K. , Eichenlaub, Udo, Vemuri, Prashanthi , Graff‐Radford, Jonathan, Jack, Clifford R. , Petersen, Ronald C. , Dage, Jeffrey L. , Jack, Clifford R , Vemuri, Prashanthi , Dage, Jeffrey L , Mielke, Michelle M. , Algeciras‐Schimnich, Alicia , Machulda, Mary M. , Knopman, David S. , Graff‐Radford, Jonathan

Mayo Clinic

Alzheimer's & Dementia | July 26, 2021 | Volume: 18 | Issue: 4 | Pages: 602-611

10.1002/alz.12415 | PMID 34310832 Get It

AbstractIntroductionThe prognostic utility of cerebrospinal fluid (CSF) phosphorylated tau 217 (p‐tau217) and p‐tau181 is not understood.MethodsAnalyses included 753 Mayo Clinic Study on Aging participants (median age = 71.6; 57% male). CSF amyloid beta (Aβ)42 and p‐tau181 were measured with Elecsys immunoassays. CSF p‐tau181 and p‐tau217 were also measured with Meso Scale Discovery (MSD). We used Cox proportional hazards models for risk of mild cognitive impairment (MCI) and linear mixed models for risk of global and domain‐specific cognitive decline and cortical thickness. Analyses were stratified by elevated brain amyloid based on CSF Aβ42 or amyloid positron emission tomography for those with imaging.ResultsCSF p‐tau217 was superior to p‐tau181 for the diagnosis of Alzheimer's disease (AD) pathology. CSF MSD p‐tau181 and p‐tau217 were associated with risk of MCI among amyloid‐positive individuals. Differences between CSF p‐tau measures predicting cortical thickness were subtle.DiscussionThere are subtle differences for CSF p‐tau217 and p‐tau181 as prognostic AD markers.
Pan‐cancer analysis of prognostic metastatic phenotypes
Wang, Xi , Garrett, Sara M. , Lehrer, Eric J. , Lin, Christine , DeGraff, David J. , Spratt, Daniel E. , Kishan, Amar U. , Park, Henry S. , Yang, Jonathan T. , Zaorsky, Nicholas G , Garrett, Sara M , Spratt, Daniel E , Park, Henry S , Zaorsky, Nicholas G. , Trifiletti, Daniel M. , Showalter, Timothy N. , Chinchilli, Vernon M , Wang, Ming

Mayo Clinic

International Journal of Cancer | July 20, 2021 | Volume: 150 | Issue: 1 | Pages: 132-141

10.1002/ijc.33744 | PMID 34287840 Get It

AbstractAlthough cancer is highly heterogeneous, all metastatic cancer is considered American Joint Committee on Cancer (AJCC) Stage IV disease. The purpose of this project was to redefine staging of metastatic cancer. Internal validation of nationally representative patient data from the National Cancer Database (n = 461 357; 2010‐2013), and external validation using the Surveillance, Epidemiology and End Results database (n = 106 595; 2014‐2015) were assessed using the concordance index for evaluation of survival prediction. A Cox proportional hazards model was used for overall survival by considering identified phenotypes (latent classes) and other confounding variables. Latent class analysis was performed for phenotype identification, where Bayesian information criterion (BIC) and sample‐size‐adjusted BIC were used to select the optimal number of distinct clusters. Kappa coefficients assessed external cluster validation. Latent class analysis identified five metastatic phenotypes with differences in overall survival (P < .0001): (Stage IVA) nearly exclusive bone‐only metastases (n = 59 049, 12.8%; median survival 12.7 months; common in lung, breast and prostate cancers); (IVB) predominant lung metastases (n = 62 491, 13.5%; 11.4 months; common in breast, stomach, kidney, ovary, uterus, thyroid, cervix and soft tissue cancers); (IVC) predominant liver/lung metastases (n = 130 014, 28.2%; 7.0 months; common in colorectum, pancreatic, lung, esophagus and stomach cancers); (IVD) bone/liver/lung metastases predominant over brain (n = 61 004, 13.2%; 5.9 months; common in lung and breast cancers); and (IVE) brain/lung metastases predominant over bone/liver (n = 148 799, 32.3%; 5.7 months; lung cancer and melanoma). Long‐term survivors were identified, particularly in Stages IVA‐B. A pan‐cancer nomogram model to predict survival (STARS: site, tumor, age, race, sex) was created, validated and provides 13% better prognostication than AJCC: 1‐month concordance index of 0.67 (95% confidence interval [CI]: 0.66‐0.67) vs 0.61 (95% CI: 0.60‐0.61). STARS is simple, uses easily accessible variables, better prognosticates survival outcomes and provides a platform to develop novel metastasis‐directed clinical trials.
Timing of Flap Coverage With Respect to Definitive Fixation in Open Tibia Fractures
Kuripla, Casey, Foote, Clary J. , Koh, Justin , Sems, Andrew, Shamaa, Tayseer , Sorg, Debra, Streufert, Benjamin D. , Spitler, Clay A. , McGowan, Brian, Weinlein, John C., Cannada, Lisa K. , Charlu, Jonathan, Wagstrom, Emily, Westberg, Jerald R., Cortez, Abigail , Marcantonio, Andrew , Soles, Gillian , Lipof, Jason S. , Tornetta, Paul , Sems, Andrew, Vallier, Heather A. , Mir, Hassan R. , Mullis, Brian , Morshed, Saam , Krause, Peter C.

Mayo Clinic

Journal of Orthopaedic Trauma | July 16, 2021 | Volume: 35 | Issue: 8 | Pages: 430-436

10.1097/bot.0000000000002033 | PMID 34267149 Get It

Objectives: We conducted a large, U.S wide, observational study of type III tibial fractures, with the hypothesis that delays between definitive fixation and flap coverage might be a substantial modifiable risk factor associated with nosocomial wound infection. Design: A retrospective analysis of a multicenter database of open tibial fractures requiring flap coverage. Setting: Fourteen level-1 trauma centers across the United States. Patients: Two hundred ninety-six (n = 296) consecutive patients with Gustilo III open tibial fractures requiring flap coverage at 14 trauma centers were retrospectively analyzed from a large orthopaedic trauma registry. We collected demographics and the details of surgical care. We investigated the patient, and treatment factors leading to infection, including the time from various points in care to the time of soft-tissue coverage. Intervention: Delay definitive fixation and flap coverage in tibial type III fractures. Main Outcome Measurements: (1) Results of multivariate regression with time from injury to coverage, debridement to coverage, and definitive fixation to coverage in the model, to determine which delay measurement was most associated with infection. (2) A second multivariate model, including other factors in addition to measures of flap delay, to provide the estimate between delay and infection after adjustment for confounding. Results: Of 296 adults (227 M: 69 F) with open Gustilo type III tibial fractures requiring flap coverage, 96 (32.4%) became infected. In the multivariate regression, the time from definitive fixation to flap coverage was most predictive of subsequent wound infection (odds ratio 1.04, 95% confidence interval 1.01 to 1.08, n = 260, P = 0.02) among the time measurements. Temporary internal fixation was not associated with an increased risk of infection in both univariate (P = 0.59) or multivariate analyses (P = 0.60). Flap failure was associated with the highest odds of infection (odds ratio 6.83, 95% confidence interval 3.26 to 14.27, P < 0.001). Conclusion: Orthoplastic teams that are dedicated to severe musculoskeletal trauma, that facilitate coordination of definitive fixation and flap coverage, will reduce the infection rates in Gustilo type III tibial fractures. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Occupational insecticide exposure and risk of non‐Hodgkin lymphoma: A pooled case‐control study from the InterLymph Consortium
Roos, Anneclaire J. De , Schinasi, Leah H. , Miligi, Lucia , Cerhan, James R. , Bhatti, Parveen , Baris, Dalsu , Benavente, Yolanda , Benke, Geza , Clavel, Jacqueline , Casabonne, Delphine, Monnereau, Alain , Vajdic, Claire M. , Wang, Sophia , Zhang, Yawei, Cocco, Pierluigi , De Roos, Anneclaire J , Vajdic, Claire M , Cerhan, James R , Cocco, Pierluigi , Wang, Sophia S , Bhatti, Parveen , Clavel, Jacqueline , Mannetje, Andrea ’t , Casabonne, Delphine , Fritschi, Lin , Hofmann, Jonathan N. , Huynh, Tran , Piro, Sara , Slager, Susan L. , Zhang, Yawei, Bernstein, Leslie

Mayo Clinic

International Journal of Cancer | July 16, 2021 | Volume: 149 | Issue: 10 | Pages: 1768-1786

10.1002/ijc.33740 | PMID 34270795 Get It

AbstractEvidence for the human health effects of pesticides is needed to inform risk assessment. We studied the relationship between occupational insecticide use and risk of non‐Hodgkin lymphoma (NHL) by pooling data from nine case‐control studies participating in the InterLymph Consortium, including 7909 cases and 8644 controls from North America, the European Union and Australia. Insecticide use was coded using self‐report or expert assessment, for insecticide groups (eg, organophosphates, pyrethroids) and active ingredients (eg, malathion, permethrin). Associations with insecticides were estimated using logistic regression to produce odds ratios (ORs) and 95% confidence intervals (CI) for all NHL and NHL subtypes, with adjustment for study site, demographic factors and use of other pesticides. Occupational insecticide use, overall, was not associated with risk of NHL. Use of organophosphate insecticides was associated with increased risk of all NHL and the subtype follicular lymphoma, and an association was found with diazinon, in particular (ever use: OR = 2.05, 95%CI: 1.24‐3.37). The carbamate insecticide, carbaryl, was associated with risk of all NHL, and the strongest associations were found with T‐cell NHL for ever‐use (OR = 2.44, 95%CI: 1.13‐5.28) and longer duration (>8 years vs never: OR = 2.90, 95%CI: 1.02‐8.25). There was no association of NHL with other broad groups of insecticides, including organochlorines and pyrethroids, and some inverse associations were estimated in relation to historical DDT use. Our findings contribute to the totality of evidence available to help inform risk decisions by public health and regulatory agencies of importance given continued, widespread use of organophosphate and carbamate insecticides.
Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation
Benning, Tyler J. , Shah, Nilay D. , Inselman, Jonathan , Houten, Holly K. Van , Ross, Joseph S. , Wyatt, Kirk D. , Inselman, Jonathan W, Ross, Joseph S

Mayo Clinic

Clinical Trials | July 16, 2021 | Volume: 18 | Issue: 6 | Pages: 732-740

10.1177/17407745211030683 | PMID 34269090 Get It

Background/Aims: The Pediatric Research Equity Act and Best Pharmaceuticals for Children Act are intended to promote the conduct of clinical trials that generate pediatric-specific evidence about drug safety and efficacy. This study assesses the quality of evidence generated through Pediatric Research Equity Act–mandated and Best Pharmaceuticals for Children Act–incentivized clinical trials of hematology/oncology drugs and characterizes subsequent changes in pediatric drug utilization rates. Methods: Trial characteristics (blinding, randomization, and comparator group) were determined for clinical trials that supported pediatric label changes. Using data from OptumLabs ® Data Warehouse, a de-identified administrative claims database, we calculated pediatric utilization rates for each drug. We calculated monthly utilization rates from January 2003 (or from the first month in which data were available) to December 2018. Results: We identified 11 hematology/oncology drugs that underwent pediatric label changes under the Pediatric Research Equity Act Pediatric Research Equity Act and/or Best Pharmaceuticals for Children Act, and we identified 15 trials supporting these changes. Of these trials, 36% (5/14) were randomized, 31% (4/13) were blinded, and 36% (5/14) used a comparator group. A median of 49 children (interquartile range 29.5) received the drug under investigation across these trials. Pediatric label changes were not associated with subsequent changes in pediatric drug utilization. Although some drugs saw increased pediatric use after gaining new pediatric indications, this pattern was not consistently observed. In addition, there was no evidence to suggest that drugs were utilized less frequently after they failed to receive pediatric indications. Conclusions: Clinical trials of hematology/oncology drugs conducted under the Pediatric Research Equity Act Pediatric Research Equity Act and Best Pharmaceuticals for Children Act generally have low methodological rigor, and the resulting label changes are not consistently associated with changes in pediatric utilization. Alternative regulatory strategies and study designs may be necessary to maximize the impact of newly generated knowledge on drug utilization.
Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report
Johnson, Skyler B. , Parsons, Matthew, Dorff, Tanya B. , Moran, Meena S. , Akerley, Wallace , Bauman, Jessica R. , Spratt, Daniel E. , Bylund, Carma L. , Swire‐Thompson, Briony , Scherer, Laura D. , Spratt, Daniel E , Parsons, Matthew, Ward, John Headley , Cohen, Stacey A. , Hubbard, Joleen M. , Onega, Tracy , Tward, Jonathan D. , Fagerlin, Angela

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 14, 2021 | Volume: 114 | Issue: 7 | Pages: 1036-1039

10.1093/jnci/djab141 | PMID 34291289 Get It

Abstract There are few data on the quality of cancer treatment information available on social media. Here, we quantify the accuracy of cancer treatment information on social media and its potential for harm. Two cancer experts reviewed 50 of the most popular social media articles on each of the 4 most common cancers. The proportion of misinformation and potential for harm were reported for all 200 articles and their association with the number of social media engagements using a 2-sample Wilcoxon rank-sum test. All statistical tests were 2-sided. Of 200 total articles, 32.5% (n = 65) contained misinformation and 30.5% (n = 61) contained harmful information. Among articles containing misinformation, 76.9% (50 of 65) contained harmful information. The median number of engagements for articles with misinformation was greater than factual articles (median [interquartile range] = 2300 [1200-4700] vs 1600 [819-4700], P = .05). The median number of engagements for articles with harmful information was statistically significantly greater than safe articles (median [interquartile range] = 2300 [1400-4700] vs 1500 [810-4700], P = .007).
Association Between Graft Choice and 6-Year Outcomes of Revision Anterior Cruciate Ligament Reconstruction in the MARS Cohort
Group, MARS, Wright, Rick W. , Huston, Laura J. , Haas, Amanda K. , Pennings, Jacquelyn S. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Stuart, Michael J., Albright, John P., Amendola, Annunziato , Andrish, Jack T. , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Brophy, Robert H. , Bush‐Joseph, Charles A., Butler, J. Brad, Campbell, John D. , Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Cox, Charles L. , Creighton, R. Alexander , Dahm, Diane L., Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Johnson, Timothy S. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, LTC Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., Wolf, Brian R. , York, James J. , Svoboda, Steven J. , Brophy, Robert H. , McCarty, Eric C , Group, MARS, Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Campbell, John D., David, Tal S. , Giffin, J. Robert , Johnson, David C., Jones, Morgan H. , McAllister, David R. , Owens, Brett D. , Shea, Kevin G. , Sherman, Orrin H. , Williams, James S.

Mayo Clinic

The American Journal of Sports Medicine | July 14, 2021 | Volume: 49 | Issue: 10 | Pages: 2589-2598

10.1177/03635465211027170 | PMID 34260326 Get It

Background: Although graft choice may be limited in the revision setting based on previously used grafts, most surgeons believe that graft choice for anterior cruciate ligament (ACL) reconstruction is an important factor related to outcome. Hypothesis: In the ACL revision setting, there would be no difference between autograft and allograft in rerupture rate and patient-reported outcomes (PROs) at 6-year follow-up. Study Design: Cohort study; Level of evidence, 2. Methods: Patients who had revision surgery were identified and prospectively enrolled in this cohort study by 83 surgeons over 52 sites. Data collected included baseline characteristics, surgical technique and pathology, and a series of validated PRO measures. Patients were followed up at 6 years and asked to complete the identical set of PRO instruments. Incidence of additional surgery and reoperation because of graft failure were also recorded. Multivariable regression models were used to determine the predictors (risk factors) of PROs, graft rerupture, and reoperation at 6 years after revision surgery. Results: A total of 1234 patients including 716 (58%) men were enrolled. A total of 325 (26%) underwent revision using a bone-patellar tendon-bone (BTB) autograft; 251 (20%), soft tissue autograft; 289 (23%), BTB allograft; 302 (25%), soft tissue allograft; and 67 (5%), other graft. Questionnaires and telephone follow-up for subsequent surgery information were obtained for 809 (66%) patients, while telephone follow-up was only obtained for an additional 128 patients for the total follow-up on 949 (77%) patients. Graft choice was a significant predictor of 6-year Marx Activity Rating Scale scores ( P = .024). Specifically, patients who received a BTB autograft for revision reconstruction had higher activity levels than did patients who received a BTB allograft (odds ratio [OR], 1.92; 95% CI, 1.25-2.94). Graft rerupture was reported in 5.8% (55/949) of patients by their 6-year follow-up: 3.5% (16/455) of patients with autografts and 8.4% (37/441) of patients with allografts. Use of a BTB autograft for revision resulted in patients being 4.2 times less likely to sustain a subsequent graft rupture than if a BTB allograft were utilized ( P = .011; 95% CI, 1.56-11.27). No significant differences were found in graft rerupture rates between BTB autograft and soft tissue autografts ( P = .87) or between BTB autografts and soft tissue allografts ( P = .36). Use of an autograft was found to be a significant predictor of having fewer reoperations within 6 years compared with using an allograft ( P = .010; OR, 0.56; 95% CI, 0.36-0.87). Conclusion: BTB and soft tissue autografts had a decreased risk in graft rerupture compared with BTB allografts. BTB autografts were associated with higher activity level than were BTB allografts at 6 years after revision reconstruction. Surgeons and patients should consider this information when choosing a graft for revision ACL reconstruction.